Loading…
CORONA Remedies (CORONA)₹2,539+0.21%Pharmaceuticals
CORONA Remedies is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 74.9 against a peer median of 43.7, and ROCE of 33.0% against a peer median of 19.0%, and latest-quarter sales growth of 22.3% against a peer median of 17.3%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shilpa Medicare | 18,303 | 61.6 | 10.9 | 9.4 | 0.25 | 0.1 | 1,533 | 243 | 45.1 | 114.9 | vs CORONA |
| Alivus Life Sciences | 18,135 | 30.0 | 24.9 | 19.0 | 0.02 | 0.3 | 2,562 | 566 | 6.3 | 31.1 | vs CORONA |
| Pfizer | 17,905 | 24.4 | 24.0 | 18.0 | 0.02 | 1.9 | 2,522 | 722 | 8.2 | 6.4 | vs CORONA |
| Eris Lifesciences | 17,536 | 24.6 | 14.0 | 18.7 | 0.60 | 0.6 | 3,118 | 651 | 12.6 | 39.5 | vs CORONA |
| Cohance Lifesciences | 16,992 | 159.6 | 8.1 | 7.1 | 0.10 | 0.0 | 2,275 | 150 | −23.2 | −198.0 | vs CORONA |
| AstraZeneca Pharma India | 16,286 | 96.2 | 29.0 | 23.3 | 0.13 | 0.6 | 2,281 | 187 | 29.8 | −32.2 | vs CORONA |
| CORONA Remedies | 15,541 | 74.9 | 33.0 | 29.5 | 0.22 | 0.4 | 1,403 | 185 | 22.3 | 15.3 | — |
| Jubilant Pharmova | 15,359 | 43.7 | 8.9 | 6.6 | 0.51 | 0.5 | 8,307 | 398 | 17.3 | −45.1 | vs CORONA |
| Natco Pharma | 14,403 | 12.6 | 17.1 | 16.9 | 0.08 | 0.6 | 4,089 | 1,414 | −44.7 | −57.1 | vs CORONA |
| Marksans Pharma | 13,979 | 27.0 | 19.0 | 15.2 | 0.11 | 0.3 | 2,954 | 421 | 35.7 | 174.2 | vs CORONA |
| Sudeep Pharma | 13,676 | 72.4 | 27.9 | 25.2 | 0.17 | 0.1 | 641 | 174 | 20.7 | 10.6 | vs CORONA |
| Peer median | 16,286 | 43.7 | 19.0 | 18.0 | 0.13 | 0.4 | 2,522 | 398 | 17.3 | 10.6 |
Listed companies closest to CORONA Remedies in Pharmaceuticals include Shilpa Medicare, Alivus Life Sciences, Pfizer, Eris Lifesciences, Cohance Lifesciences, AstraZeneca Pharma India, Jubilant Pharmova, Natco Pharma.
Shilpa Medicare, with a market cap of ₹18,303 Cr.
CORONA Remedies trades at a P/E of 74.9; the median of its peer set is 43.7. A P/E above or below the median is a description, not a judgement on value.
CORONA Remedies' return on capital employed is 33.0%, above the peer median of 19.0%.